Monoclonal antibodies in lung cancer

Bibliography

• Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008;13(Suppl 1):5-13
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• de Marinis F, Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 2008;13(Suppl 1):14-20
   PubMed Web of Science ®Google Scholar
• Belani CP, Goss G, Blumenschein G Jr. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev 2011;38:173-84
   PubMed Web of Science ®Google Scholar
• Sandomenico C, Costanzo R, Carillio G, Bevacizumab in non small cell lung cancer: development, current status and issues. Curr Med Chem 2012;19:961-71
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, von Pawel J, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med 2011;32:703-40
   PubMed Web of Science ®Google Scholar
• Jakobsen JN, Sorensen JB. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer Chemother Pharmacol 2012;69:289-99
   PubMed Web of Science ®Google Scholar
• Fargion S, Carney D, Mulshine J, Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. Cancer Res 1986;46:2633-8
   PubMed Web of Science ®Google Scholar
• Gazdar AF. Should we continue to use the term non-small-cell lung cancer? Ann Oncol 2010;21(Suppl 7):vii225-9
   PubMedGoogle Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
   PubMed Web of Science ®Google Scholar
• Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 2007;18:7-15
   PubMed Web of Science ®Google Scholar
• Lin H, Jiang J, Liang X, Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010;70:57-62
   PubMed Web of Science ®Google Scholar
• Botrel TE, Clark O, Clark L, Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis. Lung Cancer 2011;74:89-97
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Paulus R, Curran WJ, Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011;29:2312-18
   PubMed Web of Science ®Google Scholar
• Nieder C, Pawinski A, Dalhaug A, A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer. Radiat Oncol 2012;7:3
   PubMed Web of Science ®Google Scholar
• Das M, Wakelee H. Targeting VEGF in lung cancer. Expert Opin Ther Targets 2012;16:395-406
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19
   PubMed Web of Science ®Google Scholar
• Cella D, Wang M, Wagner L, Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Res Treat 2012;130:855-61
   Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
   PubMed Web of Science ®Google Scholar
• Heist RS, Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 2009;10:59-68
   PubMed Web of Science ®Google Scholar
• Buter J, Giaccone G. EGFR inhibitors in lung cancer. Oncology (Williston Park) 2005;19:1707-11. discussion 11-2, 20-3
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31
   PubMed Web of Science ®Google Scholar
• Pirker R, Filipits M. Monoclonal antibodies against EGFR in non-small cell lung cancer. Crit Rev Oncol Hematol 2011;80:1-9
   PubMed Web of Science ®Google Scholar
• Humblet Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother 2004;5:1621-33
   PubMed Web of Science ®Google Scholar
• Kurai J, Chikumi H, Hashimoto K, Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007;13:1552-61
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27
   PubMed Web of Science ®Google Scholar
• Neal JW, Heist RS, Fidias P, Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Thorac Oncol 2010;5:1855-8
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA, Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046-54
   PubMed Web of Science ®Google Scholar
• Genova C, Rijavec E, Barletta G, Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. Expert Opin Biol Ther 2012;12:939-48
   PubMed Web of Science ®Google Scholar
• Gualberto A, Karp DD. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer 2009;10:273-80
   PubMed Web of Science ®Google Scholar
• Schiller JH, von Pawel J, Schutt P, Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5:1977-85
   PubMed Web of Science ®Google Scholar
• Wakelee HA, Dahlberg SE, Brahmer JR, Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer 2012;76:410-15
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9
   PubMed Web of Science ®Google Scholar
• Crino L, Dansin E, Garrido P, Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010;11:733-40
   PubMed Web of Science ®Google Scholar
• Dansin E, Cinieri S, Garrido P, MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer 2012;76:373-9
   PubMed Web of Science ®Google Scholar
• Tassinari D, Sartori S, Papi M, Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach. Oncology 2011;80:350-8
   PubMed Web of Science ®Google Scholar
• Rosell R, Robinet G, Szczesna A, Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008;19:362-9
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Patel T, Dreisbach L, Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-17
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Harbison CT, Hart LL, Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:918-27
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, von Pawel J, Vynnychenko I, First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011;12:30-7
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. Lung Cancer 2012;77:376-82
   PubMed Web of Science ®Google Scholar
• Cho BC, Kim JH, Soo RA, The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer. Yonsei Med J 2010;51:1-8
   PubMed Web of Science ®Google Scholar
• Soo RA, Loh M, Mok TS, Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. J Thorac Oncol 2011;6:1030-8
   PubMed Web of Science ®Google Scholar
• Mok TS, Hsia TC, Tsai CM, Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. Asia Pac J Clin Oncol 2011;7(Suppl 2):4-12
   PubMedGoogle Scholar
• Tsai CM, Au JS, Chang GC, Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study. J Thorac Oncol 2011;6:1092-7
   PubMed Web of Science ®Google Scholar
• Chang JW, Thongprasert S, Wright E, An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. Asia Pac J Clin Oncol 2011;7(Suppl 2):13-21
   PubMedGoogle Scholar
• Niho S, Kunitoh H, Nokihara H, Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 2012;76:362-7
   PubMed Web of Science ®Google Scholar
• Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983-94
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Socinski MA. Targeted therapies: biomarkers in NSCLC for selecting cetuximab therapy. Nat Rev Clin Oncol 2010;7:426-8
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53
   PubMed Web of Science ®Google Scholar
• Wong DW, Leung EL, So KK, The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-33
   PubMed Web of Science ®Google Scholar
• Cappuzzo F. EGFR FISH versus mutation: different tests, different end-points. Lung Cancer 2008;60:160-5
   PubMed Web of Science ®Google Scholar
• O'Byrne KJ, Gatzemeier U, Bondarenko I, Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011;12:795-805
   PubMed Web of Science ®Google Scholar
• Trape J, Montesinos J, Catot S, A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer. Int J Biol Markers 2012;27(3):e257-62
   PubMed Web of Science ®Google Scholar
• Kimura H, Sakai K, Arao T, Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007;98:1275-80
   PubMed Web of Science ®Google Scholar
• Isola J, Tanner M, Forsyth A, Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004;10:4793-8
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Herbst RS, Olsen C, Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26:3351-7
   PubMed Web of Science ®Google Scholar
• Herbst RS, Kelly K, Chansky K, Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: southwest Oncology Group study S0342. J Clin Oncol 2010;28:4747-54
   PubMed Web of Science ®Google Scholar
• Redman MW, Crowley JJ, Herbst RS, Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819. Clin Cancer Res 2012;18:4004-12
   PubMed Web of Science ®Google Scholar
• Weihua Z, Tsan R, Huang WC, Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008;13:385-93
   PubMed Web of Science ®Google Scholar
• Dong J, Dai J, Shu Y, Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis 2010;31:1080-6
   PubMed Web of Science ®Google Scholar
• Lee SJ, Lee SY, Jeon HS, Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2005;14:571-5
   PubMed Web of Science ®Google Scholar
• Masago K, Fujita S, Kim YH, Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci 2009;100:1917-22
   PubMed Web of Science ®Google Scholar
• Ma BB, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 2010;11:75-84
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Erdem L, Olcay E, Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. Front Biosci 2011;16:116-30
   Web of Science ®Google Scholar
• Giovannetti E, Zucali PA, Peters GJ, Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther 2010;9:581-93
   PubMed Web of Science ®Google Scholar
• Heist RS, Zhai R, Liu G, VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856-62
   PubMed Web of Science ®Google Scholar
• Ma F, Sun T, Shi Y, Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer 2009;66:114-19
   PubMed Web of Science ®Google Scholar
• Vaziri SA, Kim J, Ganapathi MK, Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep 2010;12:102-8
   PubMed Web of Science ®Google Scholar
• Lee W, Jiang Z, Liu J, The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010;465:473-7
   PubMed Web of Science ®Google Scholar
• Pleasance ED, Stephens PJ, O'Meara S, A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010;463:184-90
   PubMed Web of Science ®Google Scholar
• You M, Wang D, Liu P, Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res 2009;15:2666-74
   PubMed Web of Science ®Google Scholar
• Shi J, Chatterjee N, Rotunno M, Inherited variation at chromosome 12p13.33, including RAD52, influences the risk of squamous cell lung carcinoma. Cancer Discov 2012;2:131-9
   Google Scholar
• Rini BI, Halabi S, Taylor J, Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10:2584-6
   PubMed Web of Science ®Google Scholar
• Vincenti V, Cassano C, Rocchi M, Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996;93:1493-5
   PubMed Web of Science ®Google Scholar
• An SJ, Huang YS, Chen ZH, Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. Med Oncol 2012;29:627-32
   PubMed Web of Science ®Google Scholar
• Guan X, Yin M, Wei Q, Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 2010;10:431
   PubMed Web of Science ®Google Scholar
• Yin M, Liao Z, Yuan X, Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci 2012;103:945-50
   PubMed Web of Science ®Google Scholar
• Tucker SL, Li M, Xu T, Incorporating single-nucleotide polymorphisms into the lyman model to improve prediction of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Nomura M, Shigematsu H, Li L, Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 2007;4:e125
   PubMed Web of Science ®Google Scholar
• Kim ES, Herbst RS, Wistuba II, The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53
   PubMed Web of Science ®Google Scholar
• Gold KA, Kim ES, Wistuba II, Personalizing lung cancer prevention through a reverse migration strategy. Top Curr Chem 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Sequist LV, Muzikansky A, Engelman JA. A new BATTLE in the evolving war on cancer. Cancer Discov 2011;1:14-16
   Google Scholar
• Larsen JE, Cascone T, Gerber DE, Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 2011;17:512-27
   PubMed Web of Science ®Google Scholar
• Garon EB, Cao D, Alexandris E, A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clin Lung Cancer 2012; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Schittenhelm MM, Kollmannsberger C, Oechsle K, Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol Cancer Ther 2009;8:481-9
   PubMed Web of Science ®Google Scholar
• Bebb G, Smith C, Rorke S, Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 2011;67:837-45
   PubMedGoogle Scholar
• Yamamoto N, Yamada Y, Fujiwara Y, Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol 2009;39:260-6
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Carter C, Giaccone G. Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. J Clin Oncol 2010;28:e507-10
   PubMed Web of Science ®Google Scholar
• Fury MG, Lipton A, Smith KM, A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother 2008;57:155-63
   PubMed Web of Science ®Google Scholar
• Johns TG, McKay MJ, Cvrljevic AN, MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 2010;78:572-8
   PubMed Web of Science ®Google Scholar
• Surati M, Patel P, Peterson A, Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 2011;11:1655-62
   PubMed Web of Science ®Google Scholar
• Weickhardt A, Doebele R, Oton A, A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol 2012;7:419-26
   PubMed Web of Science ®Google Scholar
• Atzori F, Tabernero J, Cervantes A, A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011;17:6304-12
   PubMed Web of Science ®Google Scholar
• Murakami H, Doi T, Yamamoto N, Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2012; Epub ahead of print
   Web of Science ®Google Scholar
• Ramalingam SS, Spigel DR, Chen D, Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011;29:4574-80
   PubMed Web of Science ®Google Scholar
• DeRose P, Thorpe PE, Gerber DE. Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. Immunotherapy 2011;3:933-44
   PubMed Web of Science ®Google Scholar
• Bayliss TJ, Smith JT, Schuster M, A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 2011;11:1663-8
   PubMed Web of Science ®Google Scholar
• Gridelli C, Bennouna J, de Castro J, Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin Lung Cancer 2011;12:407-11
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. 2011. Available from: www.clinicaltrials.gov [Accessed 18 October 2011]
   Google Scholar
• Tanaka S, Sakamori Y, Niimi M, Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST). Trials 2011;12:120
   PubMedGoogle Scholar
• Herbst RS, Ansari R, Bustin F, Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011;377:1846-54
   PubMed Web of Science ®Google Scholar
• Janku F, Garrido-Laguna I, Petruzelka LB, Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol 2011;6:1601-12
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9
   PubMed Web of Science ®Google Scholar
• Suda K, Tomizawa K, Osada H, Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer 2012;76:292-9
   PubMed Web of Science ®Google Scholar
• Gumustekin M, Kargi A, Bulut G, HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res 2012;18:209-18
   PubMed Web of Science ®Google Scholar
• Suzuki M, Shigematsu H, Iizasa T, Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 2006;106:2200-7
   PubMed Web of Science ®Google Scholar
• Takenaka M, Hanagiri T, Shinohara S, The prognostic significance of HER2 overexpression in non-small cell lung cancer. Anticancer Res 2011;31:4631-6
   PubMed Web of Science ®Google Scholar
• Dziadziuszko R, Merrick DT, Witta SE, Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010;28:2174-80
   PubMed Web of Science ®Google Scholar
• Okudela K, Suzuki M, Kageyama S, PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007;57:664-71
   PubMed Web of Science ®Google Scholar
• Xu J, He J, Yang H, Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. Cancer Biomark 2011;10:63-9
   PubMed Web of Science ®Google Scholar
• Yang F, Tang X, Riquelme E, Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res 2011;71:5512-21
   PubMed Web of Science ®Google Scholar
• Campa D, Zienolddiny S, Lind H, Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer. Lung Cancer 2007;56:17-23
   PubMed Web of Science ®Google Scholar
• Kim JS, Yim SV, Koh IS, Single-nucleotide polymorphisms (SNPs) and haplotype analysis in vascular endothelial growth factor (VEGF) gene in the patients with Parkinson disease and lung cancer. Arch Gerontol Geriatr 2009;48:287-90
   PubMed Web of Science ®Google Scholar
• Zhai R, Liu G, Zhou W, Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res 2008;14:612-17
   PubMed Web of Science ®Google Scholar
• Naik NA, Bhat IA, Afroze D, Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India). Tumour Biol 2012;33:833-9
   PubMed Web of Science ®Google Scholar
• Kim SJ, Hwang SH, Kim IJ, The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients. J Exp Clin Cancer Res 2010;29:69
   PubMed Web of Science ®Google Scholar